TD Cowen Initiates Coverage On Adarx Pharmaceuticals with Buy Rating
TD Cowen analyst Tyler Van Buren initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Buy rating.
Stocks · News reference
UBS Initiates Coverage On Adarx Pharmaceuticals with Buy Rating, Announces Price Target of $35
UBS analyst Michael Yee initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Buy rating and announces Price Target of $35.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
JP Morgan Initiates Coverage On Adarx Pharmaceuticals with Overweight Rating, Announces Price Target of $38
JP Morgan analyst Tessa Romero initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Overweight rating and announces Price Target of $38.
This Restaurant Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Analysts initiated bullish coverage on ADRX ($32), NWSA ($35), MOD ($275), SITM ($750) and QSR ($85), with Overweight, Outperform or Buy ratings.